(AOF) – Chemours is expected to rise by more than 17% in pre-market trading on Wall Street. The American chemist saw its share price plunge on February 29 after the postponement of the presentation of results and the announcement of the placing on “administrative leave” of CEO Mark Newman, financial director Jonathan Lock and chief accountant Camela Wisel, accused of fraud. An internal audit established that they had manipulated certain payments and debt collections in the fourth quarter, in particular to achieve the free cash flow objectives on which their remuneration was indexed.
Chemours announces that this will not affect preliminary results for 2023.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
